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Transfection of Human Platelets with Short Interfering RNA
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Ph.D., Ying Jin, M.D., Jay H. Herman, M.D., and Paul F. Bray, M.D.
The Cardeza Foundation for Hematologic Research and the Department of Medicine, Thomas
Jefferson University, Jefferson Medical College, Philadelphia, PA
Abstract
Platelets contain mRNAs and are capable of translating mRNA into protein and it has been
previously demonstrated that platelets increase their levels of integrin β3 over time while in Blood
Bank storage conditions. We are unaware of prior attempts to introduce nucleic acids into
platelets. Considering the potential clinical and research utility of manipulating platelet gene
expression, we tested whether small inhibitory RNAs (siRNAs) could be transfected into normal
human platelets. Multiple conditions were tested, including lipofectamine vs. electroporation,
different amounts of siRNA, the effect of different buffers and the presence of plasma during
transfection, and the time for optimal siRNA incorporation after transfection. Using flow
cytometry to assess transfection efficiency, we found that optimal transfection was obtained using
Lipofectamine, washed platelets and 400 pmoles siRNA. Cell-sorting of transfected platelets
suggested the incorporated siRNA was able to knockdown the level of a targeted mRNA. This is
the first ever demonstration that nucleic acids can be introduced directly into platelets, and offers
proof-of-concept for manipulating gene expression in platelets by non-viral methods. Future
technical improvements may permit improving the quality and/or lifespan of stored human
platelets.
Introduction
Platelet reactivity plays an important role in the pathogenesis of thrombotic and hemorrhagic
disorders. Antiplatelet agents are effective for modulating platelet prothrombotic activity.
No agents are known to enhance platelet function as might be desired in the bleeding patient
with or without thrombocytopenia, and often the only option is platelet transfusion. But the
well-characterized platelet storage lesion limits both platelet availability and function after
storage.1 Modulating inherent or acquired platelet reactivity and platelet lifespan could be of
potential benefit to patients with hemorrhagic disorders.
Because platelets are anucleate and lack the ability to transcribe DNA, there has been little
reason to attempt to modify gene expression in the platelet itself. But elegant studies have
established that platelets contain megakayocyte-transcribed mRNAs that are translated into
protein in response to physiological stimuli.2 Human platelets have been shown to
synthesize proteins like actin, thrombospondin, fibrinogen, von Willebrand factor and
membrane glycoprotiens (GPIb, integrin αIIb and integrin β3).2–4 And it is especially
noteworthy that platelets in Blood Bank storage conditions increase their levels of integrin
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β3 (the β subunit of the platelet fibrinogen receptor) over time and that the half-life of this
mRNA is longer in platelets than in several different nucleated cells.5–7
Small interfering RNA (siRNA) and microRNA (miRNA) modulate protein expression by
regulating RNA levels and/or translation. Others and we have shown that platelets express
high levels of miRNAs.8–10 Because platelet mRNA translation may be of substantial
importance and considering the potential clinical and research utility of manipulating
platelet RNA expression, we asked a simple question: can normal human platelets be
transfected with siRNA?
Methods
Platelet preparation
Blood (40 ml) was collected in 3.8% sodium citrate (1:9 citrate to blood vol/vol) from
healthy individuals under a protocol approved by the Institutional Review Board for Human
Subject Research at Thomas Jefferson University. Blood was centrifuged at 200 × g for 15
minutes to isolate platelet-rich plasma (PRP). In most experiments, platelets were washed in
modified Tyrode’s buffer (containing 138 mM NaCl, 5.5 mM dextrose, 12 mM NaHCO3,
0.8 mM CaCl2, 0.4 mM MgCl2, 2.9 mM KCl2, 0.36 mM Na2HPO4 and 20 mM Hepes, pH
7.4) in presence of 1 μM prostaglandin I2, and resuspended in the same buffer.
Platelet Transfection and mRNA Quantification
Fluorescently-labeled siRNAs for glyceraldehyde 3-phosphate dehydrogenase (FAM-
GAPDH siRNA) and a scrambled negative control (FAM-scrambled) (Ambion Inc., TX)
were used for transfection of platelets. Platelets (2 × 108 in one mL) were transfected with
siRNA using either a cationic-lipid mediated delivery or electroporation, subjected to gentle
constant shaking in a 12-well plate at room temperature and harvested at 4–48 hours.
Electroporation was performed in a Nucleofactor II® (Amaxa Inc. Walkersville, MD) using
the proprietary conditions of program X-005 (recommended for the Meg-01 cell line) and 3
different proprietary buffers. Cationic-lipid mediated delivery11 was performed using
different amounts of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in a 12-well plate.
Transfection efficiency was assessed by flow cytometry (FACScan, Becton Dickinson). In
some experiments, transfected platelets were isolated using a fluorescence activated MoFlo
High Performance Cell Sorter (Dako, Denmark) and platelet RNA was extracted using
TRIzol® (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized from 100 ng of total
RNA using Super-Script III reverse transcriptase (Invitrogen), and 10 ng of cDNA was
subjected to real-time PCR. Changes in GAPDH mRNA levels were determined by TaqMan
gene expression assays (Applied Biosystems, Foster City, CA, USA). The relative GAPDH
mRNA expression in the different experimental conditions were compared using the 2−ΔΔCt
method (ABI PRISM 7900 HT Sequence Detection System). 18S RNA was used as an
endogenous control to normalize for differences in starting cDNA levels between samples.
Results and Discussion
The major purpose of this study was to determine whether normal human platelets could be
transfected with fluorescently-labeled small inhibitory RNA (siRNA). Two methods of
transfection, electroporation and cationic-lipid mediated delivery (Lipofectamine), were
tested. All transfections utilized 2 × 108 platelets in a final volume of one mL. We initially
tested the different electroporation solutions (proprietary solutions C, V and L) provided by
the manufacturer (Amaxa Inc. Walkersville, MD). Cell counting 4 hours post transfection
revealed a ten-fold reduction in platelet number in cells transfected with solutions L and V,
suggesting these conditions induced platelet agglutination or aggregation. Electroporation
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solution C and transfection with lipofectamine produced no loss in platelet number.
However, initial flow cytometric analysis showed no platelet fluorescence in the
electroporated platelets, and a low level of fluorescence with the lipofectamine treated
platelets (not shown). Next, we tested the effect of using different amounts of the
lipofectamine reagent and the effect of transfection of washed platelets or platelets in plasma
(PRP). Flow cytometric analysis revealed a higher transfection efficiency using washed
platelets, and 6 μL lipofectamine produced more platelet fluorescence than 0, 1 or 20 μL of
lipofectamine. In addition, more fluorescence was observed 48 hours after transfection than
4 hours after transfection. Subsequent transfections utilized 6 μL lipofectamine and washed
platelets. The last set of pilot studies tested the effects of using different amounts of siRNA
and of analyzing platelet fluorescence at 24 or 48 hours after transfection. As shown in Fig.
1A, 400 nmole siRNA produced more fluorescence than 25, 100 or 200 nmole. The 24 hour
time point was slightly better than 48 hours, and post-transfection addition of 50% RPMI
with 10% fetal bovine serum was of no clear benefit.
The above studies identified the optimal transfection conditions as: 6 μL lipofectamine,
washed platelets, 400 nmol siRNA and harvest platelets for analysis at 24 hours post
transfection. Using these conditions, we observed a 70-fold higher transfection as compared
to no lipofectamine (Fig. 1B, 8.4% vs. 0.12%, shown in 2nd and 3rd panels, respectively),
indicating the effect of transfection and membrane permeabilization. Other experiments
yielded transfection efficiencies of 14% (not shown). Our experimental conditions exclude
the possibility of non-specific association of siRNA with the platelets because there was no
difference in platelet fluorescence with or without the FAM-siRNA (Fig. 1B, upper 2
panels). Thus, although the transfection efficiency was relatively low, these data
demonstrate that indeed, normal human platelets could be transfected with siRNA.
We also performed preliminary experiments to test the ability of transfected siRNA to knock
down platelet mRNA levels. Twenty-four hours after transfection, approximately 7 × 107
platelets were subjected to 4 hours of sorting on a FACS, yielding 2–5 × 106 platelets per
transfection, which were sorted directly into Trizol®. This limited yield of transfected
platelets did not permit protein assessment, but was sufficient for qPCR quantification of
mRNA. Compared to non-transfected platelets, platelets transfected with an siRNA for
GAPDH showed a 33% reduction in GAPDH mRNA (Fig. 1C, left panel). Lastly, compared
to platelets transfected with a scrambled siRNA, we observed a 26% reduction of GAPDH
mRNA in those platelets incorporating the siRNA that targets GAPDH (Fig. 1C, right
panel). We cannot exclude the unlikely possibility that the scrambled siRNA but not the
GAPDH siRNA enhanced GADPDH translation. Because we started with small blood
volumes, too few platelets remained after cell sorting to determine GAPDH protein levels.
These results offer proof-of-concept that nucleic acids can be introduced into platelets by
non-viral methods. Clearly, future efforts are needed to increase transfection efficiency and
to determine to what extent this approach can be scaled-up for research studies or clinical
use. Although our preliminary studies suggest siRNAs have the potential for modifying
platelet gene expression, future work can test knockdown of critical genes in platelet
function. Prior studies have utilized detergents to permeabilized platelets to introduce
proteins,12 and these platelets are known to retain the ability to undergo agonist-induced
platelet aggregation and secretion, but it is not known whether the conditions described in
this report will likewise retain platelet reactivity. If so, this approach would have the
potential for enhancing platelet function in stored platelets in the Blood Bank or increasing
platelet lifespan, both of which could ultimately reduce platelet transfusion need and
alloantigen exposure.
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Figure 1. Transfection of siRNA into normal human platelets
Panel A, 2×108 washed platelets suspended in 1 mL Tyrode’s buffer were transfected with 6
μL lipofectamine and 0, 25, 100, 200 or 400 pmole FAM-labeled GAPDH siRNA, and
analyzed at 24 hours by flow cytometry. Panel B, Flow cytometric histogram analysis of
platelets incubated with 6 μL lipofectamine but no siRNA (upper graph), with FAM-labeled
GAPDH siRNA but no lipofectamine (middle graph), and with both FAM-labeled GAPDH
siRNA and 6 μL lipofectamine (lower graph). X-axis of histograms is fluorescence intensity
and Y-axis is the number of platelets. Percentages in each graph indicate the percent of
transfected platelets (number in upper right quadrant divided by total number of platelets
times 100%). Panel C, siRNA-induced knock down of GAPDH mRNA compared to non-
transfected platelets (experiment #1) and compared to scrambled siRNA (experiment #2).
GAPDH mRNA expression was first normalized to 18S RNA expression and fold-changes
between GAPDH-siRNA and controls were made using the 2−ΔΔCt method.10
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